“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

As ICSs treat COPD exacerbations, people on ICSs could have fewer coded ... Second, an important question arising from this research is whether medication response is influenced by demographics or ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...

Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for exceptional importation and sale are called "designated drugs".

Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price or $325 per month after insurance. Find Cheap Health Insurance Quotes in Your Area Weight loss drugs ...